[go: up one dir, main page]

TR200100450T2 - Salvia türlerinden elde edilen ve virüslere karşı etkili olan bileşikler - Google Patents

Salvia türlerinden elde edilen ve virüslere karşı etkili olan bileşikler

Info

Publication number
TR200100450T2
TR200100450T2 TR2001/00450T TR200100450T TR200100450T2 TR 200100450 T2 TR200100450 T2 TR 200100450T2 TR 2001/00450 T TR2001/00450 T TR 2001/00450T TR 200100450 T TR200100450 T TR 200100450T TR 200100450 T2 TR200100450 T2 TR 200100450T2
Authority
TR
Turkey
Prior art keywords
compounds
effective against
compounds derived
against viruses
tetramers
Prior art date
Application number
TR2001/00450T
Other languages
English (en)
Inventor
K. Han Myun
Lee Paul
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of TR200100450T2 publication Critical patent/TR200100450T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F246/00—Copolymers in which the nature of only the monomers in minority is defined
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Formül (1), Salvia bitki cinsinin ekstratlarinda bulunan Beta-(3,4-dihidroksifenil) laktik asit ve/veya kafeik asitten olusan en azindan bir kisma sahip moleküller içeren bilesimler saglanmistir; bu kisimlar, formül (I)'e sahiptirler; aktif maddeler, en azindan 190 daltonluk bir moleküler agirliga sahiptirler. Tercih edilen maddelerin bir sinifi, bahsedilen kisimlari içeren dimerler, trimerler, tetramerler ve daha büyük polimerler olusturmak için birlesmis maddelerdir; en çok tercih edilenler, salvianolik asidin dimerleri, trimerleri, tetramerleri ve daha büyük polimerleridir. Bilesikler ve bilesimler, virüs enfeksiyonlarinin tedavi edilmesi için sistemik veya lokal olarak farmasötik olarak kabul edilebilir tasiyicilarda ve eksipiyanlarda uygulanirlar.
TR2001/00450T 1998-06-25 1999-06-25 Salvia türlerinden elde edilen ve virüslere karşı etkili olan bileşikler TR200100450T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/104,363 US6037369A (en) 1998-06-25 1998-06-25 Compounds obtained from salvia species having antiviral Activity

Publications (1)

Publication Number Publication Date
TR200100450T2 true TR200100450T2 (tr) 2001-07-23

Family

ID=22300096

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00450T TR200100450T2 (tr) 1998-06-25 1999-06-25 Salvia türlerinden elde edilen ve virüslere karşı etkili olan bileşikler

Country Status (18)

Country Link
US (1) US6037369A (tr)
EP (1) EP1089747A1 (tr)
JP (1) JP2002518455A (tr)
KR (1) KR20010071580A (tr)
CN (1) CN1312722A (tr)
AU (1) AU740698B2 (tr)
BR (1) BR9912218A (tr)
CA (1) CA2335956A1 (tr)
CZ (1) CZ20004858A3 (tr)
HU (1) HUP0103398A2 (tr)
ID (1) ID28792A (tr)
IL (1) IL140483A0 (tr)
IS (1) IS5792A (tr)
MX (1) MXPA01000195A (tr)
NO (1) NO20006631L (tr)
PL (1) PL345086A1 (tr)
TR (1) TR200100450T2 (tr)
WO (1) WO1999066942A1 (tr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5703198A (en) * 1996-12-05 1998-06-29 Georgetown University Extracts of salvia species having antiviral activity
US6043276A (en) * 1998-06-25 2000-03-28 Georgetown University School Of Medicine Compounds obtained from salvia species having antiviral activity
ATE304859T1 (de) * 2000-05-05 2005-10-15 Parsenn Produkte Ag Verwendung einer zubereitung zur topischen behandlung von durch virusinfektionen verursachten manifestationen
SG98409A1 (en) * 2000-06-21 2003-09-19 Chi Chiang Yang Pharmaceutical compositions and combinations for the treatment or prophylaxis of disorders related to hiv and retrovirus
JP2002020283A (ja) * 2000-06-22 2002-01-23 Yang Chi-Chiang Ｈｉｖおよびレトロウイルスに関連する障害の処置または予防のための薬学的組成物および組み合わせ
KR20020005222A (ko) * 2000-06-28 2002-01-17 치-치앙 양 Ｈｉｖ 또는 레트로바이러스에 관련된 질환의 치료 또는예방용 약학적 조성물 및 조합물
AU2001293048A1 (en) * 2000-09-26 2002-04-08 The Johns Hopkins University Antiviral compositions and methods of use
US20070027209A1 (en) * 2005-08-01 2007-02-01 Lee Hyun C Prevention and treatment of atherosclerosis with lithospermate B
US20100174097A1 (en) * 2007-03-28 2010-07-08 Man Kil Jung Method for isolation of high concentration of magnesium lithospermate b from salviae miltiorrhizae
US20120041062A1 (en) * 2009-03-30 2012-02-16 Tianjin Tasly Pharmaceutical Co., Ltd. Compound of salvianolic acid l, preparation method and use thereof
CN101919836A (zh) * 2009-06-17 2010-12-22 山东绿叶天然药物研究开发有限公司 迷迭香酸的新用途
CN103054976B (zh) * 2011-10-21 2014-09-24 上海中医药大学 一种治疗血小板减少症的中药组合物及其制备方法和应用
CN103845403B (zh) * 2014-02-27 2016-10-05 河南大学 丹参配方颗粒在制备预防和治疗艾滋病脑病药物方面的应用
CN104974119B (zh) * 2014-04-01 2018-10-19 中国科学院上海药物研究所 一种高纯度丹酚酸b镁及其制备方法
CN108042524A (zh) * 2017-12-21 2018-05-18 南方医科大学 丹酚酸b及其结构类似物在制备抗hpv病毒感染药物中的应用
CN109771410B (zh) * 2019-03-06 2020-11-24 湖北大学 紫草酸在制备抗乙肝病毒药物中的用途
CN109771407B (zh) * 2019-03-29 2021-11-26 成都医学院 迷迭香酸在制备抑制水痘-带状疱疹病毒的药物中的用途
CN110922286B (zh) * 2019-11-23 2022-08-16 上海化工研究院有限公司 一种非对称芳基取代富烯化合物及其制备方法与应用
WO2021221043A1 (ja) * 2020-04-30 2021-11-04 富士フイルム富山化学株式会社 ピラジン誘導体と他のコロナウイルス感染症治療薬とを組み合わせてなるコロナウイルス感染症治療剤
CN114712342B (zh) * 2022-05-10 2023-04-21 湖北大学 紫草酸在制备抗流感病毒药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178865A (en) * 1990-06-19 1993-01-12 Cedars-Sinai Medical Center Chinese herbal extracts in the treatment of hiv related disease in vitro
US5346695A (en) * 1991-03-27 1994-09-13 Tampa Bay Research Institute Methods of inhibiting HIV replication in vitro using polymers of p-hydroxylated cinnamic acids
AU5703198A (en) * 1996-12-05 1998-06-29 Georgetown University Extracts of salvia species having antiviral activity

Also Published As

Publication number Publication date
PL345086A1 (en) 2001-12-03
WO1999066942A9 (en) 2000-06-22
US6037369A (en) 2000-03-14
WO1999066942A1 (en) 1999-12-29
MXPA01000195A (es) 2002-04-24
KR20010071580A (ko) 2001-07-28
JP2002518455A (ja) 2002-06-25
HUP0103398A2 (hu) 2002-01-28
NO20006631D0 (no) 2000-12-22
ID28792A (id) 2001-07-05
IS5792A (is) 2000-12-22
CN1312722A (zh) 2001-09-12
CZ20004858A3 (cs) 2001-09-12
CA2335956A1 (en) 1999-12-29
IL140483A0 (en) 2002-02-10
AU740698B2 (en) 2001-11-15
EP1089747A1 (en) 2001-04-11
AU4714999A (en) 2000-01-10
NO20006631L (no) 2001-02-26
BR9912218A (pt) 2002-07-23

Similar Documents

Publication Publication Date Title
TR200100450T2 (tr) Salvia türlerinden elde edilen ve virüslere karşı etkili olan bileşikler
BR0013771A (pt) Composto, métodos de tratamento de uma infecção viral em um mamìfero, de inibir a transcriptase reversa do hiv, e de prevenção da infecção do hiv ou de tratar a infecção do hiv, uso de um composto, e, composição farmacêutica
BRPI0414045A (pt) administração de ligantes de tlr7 e pró-medicamentos dos mesmos para tratamento de infecção por vìrus de hepatite c
EA199901031A1 (ru) Производные бензимидазола
MY130477A (en) Pharmaceutical compositions for the treatmen of mucositis, stomatitis and behcet,s syndrome
BR0206266A (pt) Heterocìclicos de difenila substituìda útil para tratar infecção por hcv
ID21526A (id) 4-hidroksiquinolin-3-karboksamida dan hidrazida sebagai bahan anti-virus
BR0108401A (pt) Análogos de nucleosìdeos com base bicìclica modificada por carboxamidina
ID27787A (id) Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
EP1100522A4 (en) ADMINISTRATION OF ACTIVE AGENTS OVER THE LUNG
DE69934010D1 (de) Zusammensetzungen zur behandlung von chlamydiale assozierten krankheiten
ATE252081T1 (de) Neue hiv-protease-inhibitoren
PT979244E (pt) Derivados de ciclosporina, sua preparacao e composicoes farmaceuticas que os contem
EA200500804A1 (ru) Топические противоинфекционные композиции
BR9813319A (pt) Composto, composição farmacêutica para tratamento de infecções bacterianas, e, processos para tratar infecções bacterianas e para preparar um composto
MD1688G2 (ro) Benzotiofen, benzofuran şi indoltiazepinone, oxazepinone şi diazepinone, compoziţie farmaceutică, metodă de inhibare a aderării leucocitelor la celulele endoteliale pentru tratamentul proceselor inflamatorii şi metodă de tratament al mamiferelor infectate cu HIV infecţie .
DK0862634T3 (da) Farmaceutisk præparat mod papillomavirustumorer og -infektioner
BR9813317A (pt) Composto, composição farmacêutica para tratar infecções bacterianas, e, processos para tratar infecções bacterianas, e para preparar um composto
DE69500618D1 (de) Oligonukleotide mit wirkung gegen das respiratorische synzytial virus
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
RU95105983A (ru) Ингибиторы тромбина, способы их получения и фармацевтическая композиция на их основе
NO20013167D0 (no) Anvendelse av bisfosfonater for forebygging og behandling av infeksjonsprosesser
FR2791262B1 (fr) Compositions a base de chondroitine et de chitosan pour la protection, le traitement ou le remplacement des tissus conjonctifs
ATE309803T1 (de) Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung
DE69727583D1 (de) Vermeidung von gastrointestinaler schädigung